Opinion
Video
From Early Stage to Resistance: ALINA Study Insights and ALK Inhibitor Sequencing Strategies
Author(s):
Panelists discuss the findings from the ALINA study on adjuvant alectinib vs chemotherapy in resected ALK-positive NSCLC, considering how these results may influence early-stage management, sequencing strategies for ALK inhibitors, and the role of resistance mechanisms in treatment decisions.
- Dr Rotow: The ALINA study included exploratory biomarker analyses in patients with resected ALK-positive NSCLC treated with adjuvant alectinib vs chemotherapy. (Solomon BJ, et al. 2024. ESMO. 1206MO)
- What are your thoughts on these findings, and how might they impact your approach to early-stage ALK-positive NSCLC management?
- What strategies are you currently using for sequencing ALK inhibitors?
- How do resistance mechanisms influence your sequence decisions?
- What data support using lorlatinib in the first-line setting vs reserving it for later lines?
Related Videos
Related Content
